CMS Open Payments · Program Year 2024
Incyte Corporation
Incyte Corporation reported $84,406,436.77 across General Payments, Research, and Ownership to 77,737 physicians and teaching hospitals across 109,620 transactions.
- $84.4M
- All-tracks total
- 109,620
- Transactions
- 77,737
- Recipients
- −$1.4M
- General Payments vs PY2023
Incyte Corporation reported $84,406,436.77 across all CMS Open Payments tracks (General + Research + Ownership) to 77,737 physicians and teaching hospitals in Program Year 2024 - ranking #34 of 1,925 reporting manufacturers (0.6% of the all-tracks industry total); General Payments alone were $13,103,674.30, averaging $1.1K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer incyte-corporation Incyte Corporation
$84.4M · #34/1,925 · 0.6% industry · PY2024
- TOT $84.4M
- RANK #34
- SHARE 0.6%
- TXN 109,620
- RCP 77,737
- CAT 10
- GEN $13.1M
- ΔGEN −$1.4M
- TOP1 12.8%
- PY 2024
Volume peers
Nearest volume peer: Servier BioInnovation ($83.4M)
Incyte Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Incyte Corporation's CMS-reported General Payments decreased by $1.4M (−9.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INCYTE CORPORATIONPY2023: INCYTE CORPORATIONPY2024: Incyte Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $14,516,991.22
- PY2024
- $13,103,674.30
What the Data Shows for Incyte Corporation
Incyte Corporation ranks #34 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, representing 0.6% of all industry payments reported nationwide for the year. The underlying total is $84,406,436.77 across 109,620 transactions to 77,737 physicians and teaching hospitals - $769.99 per transaction and $1.1K per recipient on average.
1,983 transactions worth $4.9M make "Compensation for Services Other Than Consulting" the top general-payment category in the 10-category breakdown below, 37.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Incyte Corporation's 10-category general-payment breakdown at $4.9M, 37.0% of the reported total.
Incyte Corporation reports 10 general-payment categories - the top three are Compensation for Services Other Than Consulting (37.0%), Consulting Fee (19.8%), and Acquisitions (17.0%). The remaining 7 categories make up 26.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Incyte Corporation files across 10 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Incyte Corporation divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $4.9M | 1,983 | 37.0% |
| Consulting Fee | $2.6M | 622 | 19.8% |
| Acquisitions | $2.2M | 4 | 17.0% |
| Food and Beverage | $1.7M | 70,067 | 13.3% |
| Travel and Lodging | $862.5K | 3,139 | 6.6% |
| Space Rental or Facility Fees | $334.0K | 84 | 2.5% |
| Education | $305.4K | 1,831 | 2.3% |
| Grant | $145.0K | 3 | 1.1% |
| Royalty or License | $40.0K | 2 | 0.3% |
| Charitable Contribution | $6.4K | 2 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,874,596.74 (21.9%) of $13,103,674.30 in this company's General Payments records across 20,131 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Incyte Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Ethan Lerner
$1,678,253.33 across 1 reported transactions
- 2
Danielle Petersel
$460,463.06 across 1 reported transactions
- 3
Sandra Lee
$319,108.75 across 22 reported transactions
- 4
Serge Alexanian
$276,158.61 across 31 reported transactions
- 5
Ahmed Galal
$140,612.99 across 107 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Incyte Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Incyte Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Incyte Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
CSL Behring
Zimmer Biomet Holdings, Inc.
Celgene Corporation
BeiGene, Ltd.
Abbott Laboratories
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.